This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Amprenavir, Prozei, APV, VX-478, 141W94
Description: Agenerase is a novel, orally administered protease inhibitor.
Deal Structure: Agenerase was discovered by Vertex.
In April 1993, Vertex and Kissei Pharmaceutical signed an agreement to collaborate on the development of novel, orally active drugs for the treatment of HIV infection and AIDS. Kissei will develop and commercialize these compounds in Japan and the People's Republic of China and will pay Vertex a royalty on product sales in those countries. Kissei also has an option to acquire rights to Vertex HIV protease inhibitors in other Far Eastern countries. Vertex retains exclusive marketing rights to the compounds in North America, Europe and the rest of the world. In addition, Vertex retains manufacturing rights for bulk drug worldwide, including in the Kissei territories.
In December 1993, Vertex and Wellcome signed an agreement to collaborate on the development of novel, orally active protease inhibitors for the treatment of HIV infection and AIDS. Under the terms of the agreement, Wellcome will make payments to Vertex up to $42 million, including...See full deal structure in Biomedtracker
Partners: Kissei Pharmaceutical Co., Ltd
Pink Sheet Glaxo Wellcome Agenerase
Pink Sheet Glaxo Ziagen/Agenerase
Pink Sheet Agenerase resistance
Additional information available to subscribers only: